February 2014 Corporate Alert

Herrick is pleased to have represented Cardax Pharma, Inc., in its successful reverse merger with OTCBB-traded Koffee Korner Inc. now trading as "CDXI".  Cardax is a development stage company that is focusing first on developing products utilizing astaxanthin, a naturally occurring compound demonstrated to reduce inflammation, at its source, without the harmful side effects of current anti-inflammatory treatments such as steroids and NSAIDs. The transaction closed on February 7, 2014. 

The Herrick deal team that advised Cardax was led by partner Richard M. Morris, and included partner Louis Tuchman and counsel Sung Hyun Hwang, along with associates Liliana Chang, Regina M. Liang and Colin Bowes.